A Research Study to See How NNC0487-0111 Affects the Body's Energy Use After a Weight Loss in Adults Living With Obesity, Compared to a Low-calorie Diet or Placebo

Sponsor
Novo Nordisk A/S
Study ID
NCT07757087
Phase
PHASE1
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • NNC0487-0111 — DRUG
    NNC0487-0111 will be administered subcutaneously.
  • Placebo — DRUG
    Placebo matched to NNC0487-0111 will be administered subcutaneously.
  • LED — BEHAVIORAL
    A meal plan and meal replacements will be provided by the investigators.

Study Details

The purpose of this clinical study is to evaluate how NNC0487-0111 affects the amount of energy the body uses in people living with obesity following weight loss. This will be compared with the amount of energy used by participants who achieve weight loss through a low-calorie diet and by participants receiving placebo (without weight loss).

Key Dates

First listed
Aug 11, 2026
Start date
Aug 3, 2026
Status verified
Aug 2026
Primary completion
Sep 18, 2028
Completion
Sep 18, 2028

Study Design

Enrollment
120 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: NNC0487-0111
    Participants will receive once weekly subcutaneous injection of NNC0487-0111.
  • Placebo Comparator: Placebo
    Participants will receive once weekly subcutaneous injection of placebo matched to NNC0487-0111.
  • Other: Low Energy Diet (LED)
    Participants will receive a low-energy dietary designed to achieve a reduction in body weight.

Primary Outcome Measure

Change in sleeping metabolic rate (SMR) [ Time Frame: Baseline (week 0) to week 12-26 ]

Central Contacts

Find similar trials

Nationwide
Obesity / overweight trialsEndocrinology trialsMetabolic health trialsWeight loss trials

Related Studies